Core Viewpoint - A class action securities lawsuit has been filed against West Pharmaceutical Services, Inc. alleging securities fraud that affected investors between February 16, 2023, and February 12, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that West Pharmaceutical Services made false statements regarding its customer demand visibility and attributed headwinds to temporary COVID-related product destocking, while in reality, it was facing significant ongoing destocking in its high-margin HVP portfolio [3]. - It is alleged that West's SmartDose device, which was marketed as a high-margin growth product, actually diluted the company's profit margins due to operational inefficiencies [3]. - The margin pressures from these issues raised the risk of costly restructuring activities, including the company's exit from continuous glucose monitoring contracts with long-standing customers [3]. - As a result of these factors, the positive statements made by the defendants about the company's business, operations, and prospects were materially false and/or misleading [3]. Group 2: Next Steps for Investors - Investors who suffered losses in West Pharmaceutical Services during the specified timeframe have until July 7, 2025, to request to be appointed as lead plaintiff in the case [4]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for aggrieved shareholders and has extensive expertise in complex securities litigation [5]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the top securities litigation firms in the United States [5].

Core Viewpoint - A class action lawsuit has been filed against West Pharmaceutical Services, Inc. for allegedly misleading investors about the company's business prospects during the period from February 16, 2023, to February 12, 2025 [1][2]. Allegations - The lawsuit claims that West Pharmaceutical failed to disclose significant ongoing destocking in its high-margin HVP portfolio, contrary to its assertions of strong customer demand [2]. - It is alleged that the SmartDose device, marketed as a high-margin growth product, was actually dilutive to profit margins due to operational inefficiencies [2]. - The margin pressures faced by the company raised the risk of costly restructuring activities, including exiting continuous glucose monitoring contracts with long-standing customers [2]. - Positive statements made by the company regarding its business and prospects were claimed to be materially false or misleading [2]. Disclosure of Truth - The truth about the alleged fraud was revealed on February 13, 2025, when West issued weak revenue and earnings forecasts for 2025, attributing the disappointing guidance to the loss of two major CGM customers transitioning to in-house manufacturing [3]. - West also indicated that its SmartDose devices would be margin dilutive in 2025 and mentioned that steps would be taken to improve the economics of the SmartDose [3]. - Following this announcement, West's stock price fell by $123.17 per share, a decline of approximately 38%, closing at $199.11 on February 13, 2025 [3]. Class Action Participation - Shareholders interested in serving as lead plaintiffs in the class action must file their papers with the court by July 7, 2025 [4]. - Shareholders can remain absent class members and still be eligible for recovery without participating in the case [4]. About Robbins LLP - Robbins LLP is recognized for its work in shareholder rights litigation, focusing on helping shareholders recover losses and improve corporate governance since 2002 [5].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of West Pharmaceutical Services, Inc. regarding a class action lawsuit due to alleged misleading statements and operational inefficiencies that impacted the company's financial performance during the specified class period [1][3]. Summary by Relevant Sections Class Period and Allegations - The class period for the lawsuit is from February 16, 2023, to February 12, 2025 [3]. - Allegations include: - The company claimed strong visibility into customer demand while actually facing significant destocking in its high-margin HVP portfolio [3]. - The SmartDose device, marketed as a high-margin growth product, was found to be dilutive to profit margins due to operational inefficiencies [3]. - Margin pressures raised the risk of costly restructuring activities, including exiting continuous glucose monitoring contracts with long-term customers [3]. - Positive statements made by the defendants regarding the company's business and prospects were materially false or misleading [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by July 7, 2025, to participate in potential recovery [4]. - Upon registration, shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle [4]. Law Firm's Commitment - The Gross Law Firm aims to protect investors' rights and ensure companies adhere to responsible business practices [5]. - The firm seeks recovery for investors who suffered losses due to false or misleading statements that inflated the company's stock value [5].

NEW YORK, June 12, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of West Pharmaceutical Services, Inc. (NYSE: WST).Shareholders who purchased shares of WST during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/west-pharmaceutical-services-inc-loss-submission-form/?id=152569&from=4CLA ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of West Pharmaceutical Services, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on July 7, 2025 [1] Group 1: Class Action Details - Investors who bought West common stock between February 16, 2023, and February 12, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6] - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions [4] Group 2: Case Allegations - The lawsuit alleges that West Pharmaceutical Services made false and misleading statements regarding its business operations, particularly concerning its High-Value Products portfolio and the SmartDose device [5] - Specific claims include that West was experiencing significant destocking in its high-margin products, contrary to its public statements, and that operational inefficiencies were negatively impacting profit margins [5] - The lawsuit asserts that these misleading statements led to investor damages when the true situation was revealed [5]

Core Viewpoint - A class action securities lawsuit has been filed against West Pharmaceutical Services, Inc. alleging securities fraud that negatively impacted investors between February 16, 2023, and February 12, 2025 [1][2]. Summary by Sections Class Definition - The lawsuit aims to recover losses for investors adversely affected by alleged securities fraud during the specified period [2]. Case Details - The complaint alleges that West Pharmaceutical Services made false statements and concealed significant issues, including: - The company was experiencing ongoing destocking in its high-margin HVP portfolio, contrary to claims of strong visibility into customer demand [3]. - The SmartDose device, marketed as a high-margin growth product, was actually dilutive to profit margins due to operational inefficiencies [3]. - Margin pressures raised the risk of costly restructuring activities, including exiting continuous glucose monitoring contracts with long-term customers [3]. - Positive statements made by the defendants regarding the company's business and prospects were materially false or misleading [3]. Next Steps - Investors who suffered losses during the relevant timeframe have until July 7, 2025, to request appointment as lead plaintiff, although participation does not require serving in this role [4]. Why Levi & Korsinsky - Levi & Korsinsky has a strong track record in securities litigation, having secured hundreds of millions for shareholders and consistently ranking among the top securities litigation firms in the U.S. [5].

Core Viewpoint - West Pharmaceutical Services (WST) shows potential for significant upside, with a mean price target of $284 indicating a 26.9% increase from the current price of $223.77 [1] Price Targets and Analyst Consensus - The average price target for WST ranges from a low of $245 to a high of $355, with a standard deviation of $34.94, indicating variability in analyst estimates [2] - The lowest estimate suggests a 9.5% increase, while the highest points to a 58.7% upside [2] - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Market Sentiment - Analysts have shown increasing optimism about WST's earnings prospects, with a positive trend in earnings estimate revisions [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 0.2%, with one estimate moving higher and no negative revisions [12] - WST holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - Solely relying on price targets for investment decisions may not be wise, as empirical research indicates that they often mislead investors [7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

NEW YORK, June 10, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in West Pharmaceutical Services, Inc. ("West Pharmaceutical Services, Inc." or the "Company") (NYSE: WST) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of West Pharmaceutical Services, Inc. investors who were adversely affected by alleged securities fraud between February 16, 2023 and February 12, 2025. Follow the link below to get more information and be contacted by a mem ...

NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of West Pharmaceutical Services, Inc. (NYSE: WST). Shareholders who purchased shares of WST during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/west-pharmaceutical-services-inc-loss-submission-form/?id=151935&fr ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of West Pharmaceutical Services, Inc. regarding a class action lawsuit alleging that the company made materially false and misleading statements during the class period from February 16, 2023, to February 12, 2025 [1]. Group 1: Allegations - The complaint alleges that West Pharmaceutical Services claimed strong visibility into customer demand while actually experiencing significant destocking in its high-margin HVP portfolio [1]. - The SmartDose device, positioned as a high-margin growth product, was found to be dilutive to profit margins due to operational inefficiencies [1]. - Margin pressures from these issues raised the risk of costly restructuring activities, including exiting continuous glucose monitoring contracts with longstanding customers [1]. - Positive statements made by the defendants regarding the company's business and prospects were deemed materially false or misleading [1]. Group 2: Class Action Details - Shareholders who purchased shares of WST during the specified class period are encouraged to register for the class action, with a deadline of July 7, 2025, to seek lead plaintiff status [2]. - Registered shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [2]. - Participation in the case incurs no cost or obligation for shareholders [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [3].